References:
1.WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. World Health Organization (Geneva) in 2014;
2.Vaisbuch E, Whitty JE, Hassan SS, Romero R, Kusanovic JP, et al. Circulating angiogenic and antiangiogenic factors in women with eclampsia. Am J Obstet Gynecol.2011;204:152.e1-9. Link:https://tinyurl.com/yco44x9m
3.Redman CW. Preeclampsia: a multi-stress disorder. Rev Med Interne. 2011;32(1):41-4.
4.Redman CWG. The six stages of pre-eclampsia. Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health. 2014; 4(3):246.
5.Akolekar R, Syngelaki A, Poon L, et al. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther 2013;33(1):8-15.
6.Thilaganathan В. Placental syndromes: getting to the heart of the matter. Ultrasound Obstet Gynecol. 2017; 49:7–9. DOI: 10.1002/uog.17378
7.L’Abee C., Vrieze I, Kluck T, Erwich JJHM, Stolk RP, Sauer PJJ. Parental factors affecting the weights of the placenta and the offspring. J Perinat Med. 2011;39:27-34.
8.J.M. Wallace, G.W. Horgan, S. Bhattacharya. Placental weight and efficiency in relation to maternal body mass index and the risk of pregnancy complications in women delivering singleton babies. Placenta. 2012;33:611- 618
9.Prabhjot Kaur, Subhash Kaushal, Kuljit Singh and Ashish Sharma. Placental weight, birth weight and fetal outcome in preeclampsia and normotensive pregnancies. International Journal of Plant, Animal and Environmental Sciences. 2013; 3: 31-34.
10.M. J. Quinn. Preeclampsia: 2 placental phenotypes, 1 etiology? American Journal of Obstetrics & Gynecology. 2014;211(3):313-314.
11.Johanne Dypvik, Sandra Larsen, Camilla Haavaldsen, Anne M. Jukic, Lars J. Vatten, Anne Eskild. Placental weight in the first pregnancy and risk for preeclampsia in the second pregnancy: A population-based study of 186 859 women. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2017;214:184–189.
12.L.K. Proctor, B. Fitzgerald, W.L. Whittle, N. Mokhtari, E. Lee, G. Machin, J.C.P. Kingdom,S.J. Keating. Umbilical cord diameter percentile curves and their correlation to birth weight and placental pathology. Placenta. 2013;34: 62- 66.
13.Siveska EJ, Jasovic V. Fetal Growth and Body Proportion during Pre-Eclamptic Pregnancy. Obstet Gynecol Int J. 2015;2(3): 00038. DOI:10.15406/ogij.2015.02.00038
14.Bhattacharjee AK, Majumdar MK, Lucky Basumatary Sch. Placental Laterality by Ultrasound and Its Correlation to Development of Pre-eclampsia. J. App. Med. Sci., Oct 2017; 5(10F):4197-4200
15.Parul S. Jani, Uday M. Patel, Mayur R. Gandhi, Nilesh C. Thakor, C. R. Kakani Placental laterality and uterine artery resistance as predictor of preeclampsia: a prospective study at GMERS Medical College, Dharpur-Patan, North Gujarat, India. Int J Res Med Sci. 2015 Jun;3(6):1484-1487
16.Merkusheva L.I., Kozlovskaya N.L. Current ideas on the pathogenesis of renal injury in preeclampsia. Obstetrics and Gynecology. 2015;8:12-17.
17.U.S. Preventive Services Task Force. MONDAY, Sept. 8, 2014 (HealthDay News) https://www.medicinenet.com/script/main/art.asp?articlekey=180570
18.Vellanki, K. Pregnancy in Chronic Kidney Disease. Adv. Chronic Kidney Dis. 2013;20(3):223–228.
19.N Kevin Krane. Renal Disease and Pregnancy// 2015; https://emedicine.medscape.com/article/246123-overview
20.Waring W.S. et al. Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury. Clin. Toxicol. 2011;49(8):720-728.
21.Y. Padma et. al. Renal markers in normal and hypertensive disorders of pregnancy in Indian women: a pilot study. International Journal of Reproduction, Contraception, Obstetrics and Gynecology. 2013;2(4):514–520.
22.Apeksha Niraula et. al. Cystatin-C as a Marker for Renal Impairment in Preeclampsia. Journal of Biomarkers. 2017, Article ID 7406959, 7 pages https://doi.org/10.1155/2017/7406959
23.Вельков В.В. Цистатин С и NGAL — маркеры преклинической ренальной дисфункции и субклинического острого повреждения почек. Лабораторная служба. 2015;(2):38 – 43.
24.Grigorios Karampas et. al. Maternal serum levels of neutrophil gelatinase-associated lipocalin(NGAL), matrix metalloproteinase-9 (MMP-9) and their complex MMP-9/NGAL in pregnancies with preeclampsia and those with a small for gestational age neonate: a longitudinal study. Prenatal Diagnosis. 2014; 34:726–733.
25.Sun Min Kim et. al. Circulating Levels of Neutrophil Gelatinase–Associated Lipocalin (NGAL) Correlate With the Presence and Severity of Preeclampsia. Reproductive Sciences. 2013;20(9):1083–1089.
26.Nilgün Tekkeşin. Maternal urinary NGAL levels for diagnosis of preeclampsia in pregnant woman: a protential diagnostic biomarker. Nobel Med. 2015;11(3): 37 – 41.
27.Simonazzi G. et. al. Serum and Urinary Neutrophil Gelatinase-associated Lipocalin Monitoring in Normal Pregnancy Versus Pregnancies Complicated by Pre-eclampsia. in vivo. 2015;29:117-122.
28.Ødum L. et. al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) excretion increases in normal pregnancy but not in preeclampsia. Clin Chem Lab Med. 2014;52(2):221-5.
29.Yuping Wang et. al. Increased urinary levels of podocyte glycoproteins, matrix metallopeptidases, inflammatory cytokines, and kidney injury biomarkers in women with preeclampsia. Am J Physiol Renal Physiol. 2015;309:1009 – 1017.